Amgen chooses Generate in $1.9B biobucks deal to churn out up to 10 multispecific drugs

[cafead]

via Amgen wants its future drugs to be multispecific, and so the biopharmaceutical company selected Generate Biomedicines for a $1.9 billion biobucks deal to initially create five programs across several diseases.

article source